bluuebunny/crossref_metadata_2025 huggingface dataset:
Predictors of success for Brugada syndrome epicardial ablation
Authors: Grossi S , Bianchi F , Blandino A , Sibona Masi A , Pintor C , Musumeci G
Published: November 2020

Epicardial right ventricular outflow tract (RVOT) ablation has been described for the treatement of Brugada syndrome (BrS) high risk patients.

Purpose

Success evaluation of epicardial ablation for BrS.

Methods

Type 1 ECG was defined as spontaneous if recorded in absence of drugs and/or specific conditions. BrS patients were scheduled for ablation if presented at least one of: spontaneous type 1 ECG, syncope, ventricular arrhythmias (VA).

Programmed electrical stimulation (PES) was performed (2 extrastimuli, 2 sites) in basal conditions and after ajmaline infusion. Epicardial subxifoid access and electroanatomical endo-epicardial maps were obtained during sinus rhythm. Delayed fragmented/low-frequency, low-voltage electrograms (EGM) were targeted: substrate area measured in basal conditions and after ajmaline.

Epicardial ablation

Radiofrequency (RF) was delivered (50 W power control mode) till complete elimination of targeted EGM and BrS-ECG pattern after ajmaline. Eventually PES repeated: if positive a repeated PES scheduled at follow-up (fu).

Success was defined as absence of type 1 ECG either spontaneous or with ajmaline challenge at 3 month. Recurrences were scheduled to redo ablation.

Results

55 patients were submitted to 58 ablation procedures. 38 spontaneous type 1 ECG: 18 symptomatic for syncope/polimorphic VT/VF or appropriate ICD shock; 13 had VA induction at PES. 4 patients with ajmaline-type 1 ECG had VA induction. 36% of the symptomatic patients and 26% of asymptomatic had PES-VA induction. In all patients abnormal EGM area (cm2) was detected in epicardial RVOT (table 1).

Acute success: No patient had ECG type 1 with ajmaline. 5 patients had PES induction of VA. Complications: 1 cardiac tamponade, 16 mild pericarditis.

At FU of 1,1±0,6 yrs no patient had spontaneous ECG type 1 nor arrhythmic events. 50 had negative ajmaline challenge (90% success rate after single procedure), 3 underwent redo: 2 had negative ajmaline challenge at FU, 1 had persistence type 1-ajmaline induction; 2 are scheduled for redo. No patient had VT induction at PES.

Multivariate analysis: Single procedure success was not related either to history (symptoms, VA, type 1 ECG) or to procedural findings (PES results, substrate area).

Conclusion

Epicardial substrate ablation was safe end effective in BrS. No clinical or procedural findings were related to success

Funding Acknowledgement

Type of funding source: None
Analysis on the factors related to the acute success rate of fluoroless catheter ablation in patients with supraventricular tachycardias: a single-center experience
Authors: Jan M , Yazici M , Habjan S , Prolic Kalinsek T , Topalovic M , Zizek D , Stublar J , Rupar K , Lakic N
Published: November 2020

Background

In this retrospective study, we aimed to detect factors related to the acute success rate (ASR) of radiofrequency (RFA) and cryo-ablation (CRA) of SVTs guided by three-dimensional (3D) electroanatomical mapping (EAM) system completely without the use of fluoroscopy (FLR).

Methods and results

We analyzed 324 consecutive patients with SVTs [age was 30.65±20.71 (3.6–83.1) years, 147 patients <19 years old and 50.3% (163/224) patients were female]. There were 112 patients with accessory pathways (APs), 36 patients with atrial tachycardia (ATs), and 176 patients with atrioventricular nodal reentrant tachycardia (AVNRT). All procedures [(RFA (n=257), CRA (n=51), combined RFA and CRA (n=16)] were performed guided by the 3D EAM system completely without the use of FLR. Intracardiac echocardiography (ICE) was used as an imaging tool when transseptal approach was needed for treatment of left-sided arrhythmias. The acute success rate (ASR) was 90.4% (293/224). There were no procedural complications. After the first procedure, patients were divided into the “ablation success” group (group I, n=293) and the “ablation failure” group (group II, n=31). Two groups were similar in terms of age, BMI, gender distribution, and type of ablation procedure. In group II, number of ablation lesions was significantly higher than group I [respectively; 17.93±11.7 vs. 10.5±14.5; p=0.003]. Additionally, total ablation time (TAT) [respectively; 552.6±298.6 vs. 449.7±448.1; p=0.1] and total procedural time (TPT) [respectively; 116.3±54.2 vs. 94.5±82.0; p=0.05] were mildly higher. When compared to Group I, the number of patients with right-sided tachycardias was significantly higher in Group II.[67.74% (21/31 vs. 21.5% (63/293; p<0.001]. ASR was the highest for patients with AVNRT and lowest for patients with ATs [respectively; 95.4% (168/176) vs. 75.0% (27/36); p<0.001]. Binary logistic regression analysis (Nagelkerke R Square=0.201) showed that SVTs originating from the right side were an independent risk factor for procedural failure. Patients with right-sided SVTs faced an approximately 11-fold increased risk of failed ablation (OR=10.69, 95% CI 2.49–45.78, p=0.001). Type of arrhythmia, type of ablation procedure, the sex category, age, and BMI were not independent risk factors for failed ablation. A significant risk factor for recurrence could not be detected.

Conclusions

This study revealed that catheter ablation of SVTs completely without the use of fluoroscopy can be performed with high ASR and without procedural complications. Likewise, ASR of fluoroless ablation was the highest for patients with AVNRT and lowest for patients with AT. Moreover, right-sided SVTs were an independent risk factor for ablation failure.

Funding Acknowledgement

Type of funding source: None
Pre-ablation left atrial function predicts the presence of low voltage zone in patients undergoing paroxysmal atrial fibrillation ablation: OLAF-LVZ predictive score
Authors: Oka T , Yoshimoto I , Koyama Y , Tanaka K , Hirao Y , Tanaka N , Okada M , Kitagaki R , Okamura A , Iwakura K , Fujii K , Inoue K
Published: November 2020

Background

Preoperative left atrial (LA) function is associated with paroxysmal atrial fibrillation (PAF) ablation outcome. The presence of left atrial low voltage zone (LVZ) is also associated with recurrence. We hypothesized that reduced pre-ablation LA function reflects the presence of LVZ.

Purpose

We investigated the association between baseline LA function and the presence of LVZ in patients undergoing initial PAF ablation. Further, we sought to create the new predictive scoring for the presence of LVZ.

Methods

Consecutive 305 patients who underwent LA voltage mapping during initial PAF ablation from January 2017 to October 2019 in our institute were retrospectively analyzed. We performed 256-slice MDCT at baseline. As the representative of LA function, we calculated LA emptying fraction (LAEF), where LAEF = {[(maximum LAV) − (minimum LAV)]/(maximum LAV)} x 100. LVZ was defined as regions where bipolar peak-to-peak voltage was <0.5mV. We performed the univariate and multivariate analysis to assess the association between LAEF and the presence of LVZ. Second, we performed receiver operating characteristic (ROC) analysis for the prediction of LVZ. We combined multivariate predictors and created the predictive scoring for LVZ.

Results

Out of 305 pts, 56 pts (18%) had LVZ in LA. In univariate analysis, low body mass index, higher percentage of female sex, higher age, higher E/e', larger maximum LA volume and lower LAEF (29.3±11.8% vs. 41.2±9.7, P<0.0001) was associated with the presence of LVZ. In multivariate logistic regression analysis, Low LAEF revealed the strongest predictor for LVZ (LAEF; Odds ratio [OR]/10% increase: 0.54, 95% CI: 0.39–0.82, P=0.0016). High age and female sex also remained as the independent predictors (Age; OR/10 y.o. increase: 1.80, 1.23–3.03, P=0.0042, Female; OR: 2.51, 1.15–5.49, P=0.0213). In ROC analysis, LAEF had moderate predictive accuracy for the presence of LVZ. (Area under the ROC curve: 0.77, Best cut-off value: 31%, P<0.0001) (Figure 1). We created OLAF-LVZ predictive score by combining Old age (1 point, ≥65), LAEF (2 points, LAEF ≤31%) and Female sex (1 point). OLAF score had gradient effect on the incidence of LVZ (2%, 11%, 25%, 45%, 71%, OLAF score; 0, 1, 2, 3, 4, respectively, P<0.0001) (Figure 2).

Conclusions

In PAF patients, preoperative LAEF was strongly associated with the presence of LVZ. LVZ might reflect the myocardial injury causing LA dysfunction. OLAF-LVZ predictive score: combination of Old age (≥65), Female sex, and LAEF (≤31%) could be useful to stratify the risk of the presence of LVZ.

Funding Acknowledgement

Type of funding source: None
Endocardial vs endo-epicardial ablation of ventricular arrhythmia in arrhythmogenic right ventricular cardiomyopathy: a single center experience
Authors: Simonova K.A , Kamenev A.V , Tatarskiy R.B , Naymushin M.A , Orshanskaya V.S , Lebedeva V.K , Garkina S.V , Vander M.A , Vakhrushev A.D , Lebedev D.S , Mikhaylov E.N
Published: November 2020

Background

The majority of patients have a sub-epicardial scar as a substrate for VT episodes.

Purpose

We sought to compare the efficacy of endocardial (ENDO) and epicardial (EPI) substrate modification in patients with ARVC.

Methods

20 consecutive ARVC patients (mean age 41,4±13,8, 70% males; ICD previously implanted in 10 patients) with indications to ventricular arrhythmia ablation (RFA) were included into a prospective observational study. The EPI group consisted of 10 patients with sustained ventricular tachycardia (VT) (definite diagnosis ARVC – 8 patients; borderline – 1, possible – 1) who signed an informed consent to epicardial access. The ENDO group included 10 patients (definite diagnosis ARVC – 9 patients), five of them demonstrated sustained VT and 5 patients had frequent symptomatic premature ventricular contractions (PVC). Epicardial access in the EPI group was obtained through subxyphoid puncture. Bi- and unipolar voltage mapping of endocardial and epicardial surfaces was performed. Maps were evaluated for the presence of local abnormal ventricular electrical activity (LAVA, low-voltage areas and sites with highly fractionated or late activity). Ablation was performed at sites of LAVA on either side of the ventricular wall. In the ENDO group endocardial only ablation at LAVA sites was performed. RF energy ablation was 40W at the epicardial surface and 40–50W at the endocardial surface.

Results

In the EPI group endocardially mapped area of unipolar endocardial low voltage zone (LVZ) significantly prevailed over bipolar endocardial area of LVZ: 75.4 cm2 [IQR: 23.2; 211.9] vs 6.7 cm2 [IQR: 4.4; 35.5](P=0.009). Epicardial bipolar LVZ area prevailed over unipolar epicardial LVZ area: 65.3 cm2 [IQR: 55.6; 91.3] vs 6.7 cm2 [IQR: 4.4; 35.3] (P=0.005). Endocardial unipolar LVZ area in the EPI group was larger than in the ENDO group (P>0,05). After ablation non-inducibility of any ventricular arrhythmia was achieved in 90% of patients in the EPI group and in 80% of cases in the ENDO group. During a mean follow-up period of 22.3±10.5 months freedom of ventricular arrhythmia recurrence was 70% in the EPI group and 100% in the control group.

Conclusions

Although epicardial area of abnormal potentials significantly prevails over endocardial area, endocardial unipolar mapping and higher RF ablation power allow performing successful ventricular arrhythmia treatment in the majority of ARVC patients.

Funding Acknowledgement

Type of funding source: None
Sustained ventricular tachycardia of left, right or both bundle branch block morphology in patients with Arrhythmogenic Cardiomyopathy
Authors: Milman A , Laredo M , Roudijk R , Peretto G , Andorin A , Sellal J.M , Duru F , Arbelo E , Lacroix D , Maury P , Peichl P , Fauchier L , Miles C , Zehavi G , Belhassen B
Published: November 2020

Aims

In arrhythmogenic cardiomyopathy (ACM) sustained monomorphic ventricular tachycardia (VT) typically displays left bundle branch block (LBBB) morphology. Sustained VT with right bundle branch block (RBBB) morphology is very rare despite the frequent left ventricular involvement. The present study sought to assess the prevalence of spontaneous sustained LBBB-VT, RBBB-VT or both as well as clinical and genetic differences associated with these VT types.

Methods and results

Twenty-six centers from 11 European countries provided information on 952 patients with ACM and >1 episode of sustained VT observed during the patients' clinical course. VT was classified as: LBBB-VT; RBBB-VT or LBBB+RBBB-VT.

Among 952 patients, 881 (92.5%) had LBBB-VT alone, 71 (7.5%) had RBBB-VT [alone in 42 (4.4%) patients or with LBBB-VT in 29 (3.0%) patients]. Male prevalence was 90.5%, 79.2% and 55.9% in the RBBB-VT, LBBB-VT and LBBB+RBBB-VT groups, respectively (P=0.001). Patients' age at first VT did not differ amongst the 3 VT groups. ICD implantation was more frequent for the RBBB-VT and the LBBB+RBBB groups (≈90% each) vs. 67.9% for the LBBB-VT group (P=0.001). Death incidence (9.5%–17.2%) was not significantly different between the 3 groups (P=0.425). Plakophylin-2 mutations predominated in the LBBB-VT and LBBB-VT+RBBB-VT groups (47.2% and 27.3%, respectively) and Desmoplakin mutations in the RBBB-VT group (36.7%).

Conclusion

This large European survey demonstrates: 1) Sustained RBBB-VT is documented in 7.5% patients with ACM; 2) Males markedly predominate in the RBBB-VT and LBBB-VT groups but not in the LBBB+RBBB VT group; 3) Distribution of desmosomal mutations appears to be different in the 3 VT groups.

Funding Acknowledgement

Type of funding source: None
Toll-like receptor 9 is a novel therapeutic target to prevent atrial fibrillation
Authors: Soeki T , Matsumoto K , Fukuda D , Uematsu E , Matsuura T , Tobiume T , Kusunose K , Ise T , Yamaguchi K , Yagi S , Yamada H , Wakatsuki T , Sata M
Published: November 2020

Background

Atrial fibrillation (AF) is the most common type of arrhythmia seen in clinical practice. Recent studies suggest that inflammation contributes to the pathogenesis of AF. On the other hand, several evidence suggests that toll-like receptor (TLR) 9 recognizes bacterial DNA, activating innate immunity, whereas it also provokes inflammation in response to fragmented DNA released from mammalian cells. Recently, we have reported that TLR 9 plays a pivotal role in the development of vascular inflammation and atherogenesis through proinflammatory activation of macrophages.

Purpose

This study aimed to assess whether TLR9 contributes to the AF arrhythmogenesis.

Methods

TLR9 deficient (TLR9−/−) and wild-type mice were infused with angiotensin II (Ang II) or vehicle via an osmotic minipump for 4 weeks. Blood pressure and body weight were measured serially. Then, we examined AF inducibility by intracardiac electrophysiological study and the inflammation-induced atrial remodeling by biochemical analysis after 4 weeks of Ang II infusion.

Results

There was no significant difference in blood pressure and pulse rate between TLR9−/− and wild-type mice both before and after Ang II infusion. Ang II-treated TLR9−/− mice showed lower incidence of AF compared with wild-type mice treated with Ang II. Genetic deletion of TLR9 significantly reduced the interstitial fibrosis in atrium of Ang II-treated mice. TLR9−/− mice also showed less mRNA expressions of inflammatory and fibrosis-related biomarkers (TNF-α, interleukin-6, TGF-β, collagen-1, collagen-3) in atrium compared with wild-type mice.

Conclusions

TLR9 might contribute to the AF arrhythmogenesis associated with atrial inflammation. TLR9 might serve as a potential therapeutic target for AF.

Funding Acknowledgement

Type of funding source: None
Genetic susceptibility, elevated blood pressure and risk of atrial fibrillation
Authors: Nazarzadeh M , Pinho-Gomes A , Bidel Z , Canoy D , Dehghan A , Smith Byrne K , Bennett D , Davey Smith G , Rahimi K
Published: November 2020

Background

Whether elevated blood pressure (BP) is a modifiable risk factor for atrial fibrillation (AF) is not established.

Purpose

We tested (1) whether the association between BP and risk of AF is causal, (2) whether it varies according to individual's genetic susceptibility for AF, and (3) the extent to which specific BP-lowering drugs are expected to reduce this risk.

Methods

First, causality of association was assessed through two-sample Mendelian Randomization (MR), using data from two independent genome-wide association studies that included a total of one million European population. Second, UK Biobank individual participant data of 329,237 participants at baseline was used to study the effect of BP on AF according to genetic susceptibility of developing AF. Third, a possible treatment effect with BP-lowering drug classes on AF risk was predicted through genetic variants in druggable genes that code proteins related to the function of each drug class. Estimated drug effects were compared with effects on incident coronary heart disease, for which direct trial evidence exists.

Results

The two-sample MR analysis indicated that on average each 10-mm Hg increment in systolic BP increased the risk of AF (odds ratio [OR]: 1.23 [1.11 to 1.36]). This association was replicated in the UK biobank using individual participant data. However, in a further genetic risk-stratified analysis, there was evidence for a linear gradient in the relative effects of systolic BP on AF; while there was no conclusive evidence of an effect in those with low genetic risk, a strong effect was observed among those with high genetic susceptibility for AF (Figure). The indirect comparison of predicted treatment effects using genetic proxies for three main drug classes (angiotensin-converting enzyme inhibitors, beta-blockers and calcium channel blockers) suggested similar average effects for prevention of atrial fibrillation and coronary heart disease.

Conclusions

The association between elevated BP and higher risk of AF is likely to be causal, suggesting that BP-lowering treatment may be effective in AF prevention. However, average effects masked clinically important variations, with a more pronounced effect in individuals with high genetic susceptibility.

Figure 1

Funding Acknowledgement

Type of funding source: Foundation. Main funding source(s): British Heart Foundation
Levels of platelet derived extracellular vesicles in the left atrial appendage are higher in patients with permanent atrial fibrillation
Authors: Zietzer A , Al-Kassou B , Jamme P , Steffen E , Werner N , Nickenig G , Jansen F
Published: November 2020

Introduction

Atrial fibrillation (AF) is a frequent arrhythmic disease and one of the most important causes of thrombembolic disease due to intracardiac thrombus formation. The left atrial appendage has been identified as the structure, where thrombus formation typically takes place in AF patients. Previous studies have shown thrombus formation is more frequent in permanent, than in paroxysmal or persistent AF. Underlying causes for this finding, however, remain unclear. Recently, it has been shown, that large extracellular vesicles (Microvesicles, MVs) are mediators of platelet activation. The aim of this study is therefore to investigate if the AF subtype correlates with the regional abundance of platelet derived MVs in the left atrial appendage.

Methods and results

In order to address this question blood samples from 59 consecutive patients undergoing left and right atrial catheterization were collected from the right atrium (RA), the left atrium (LA) and the left atrial appendage (LAA). 49% of the patients had permanent AF, 34% had non-permanent AF and 17% had no history of AF. MVs were isolated from 150 μL citrate plasma by a four-step differential centrifugation protocol (20000g x 40 min as main pelleting step). The MVs were characterized by immunoblotting and nanoparticle tracking analysis. The size of the MVs ranged between 50 and 600 nm and the MVs were shown to carry typical markers such as Annexin V. For flowcytometric analysis and quantification, Calcein AM was used to identify vesicles and CD31-PE, CD41-APC, CD235a-PE-Cy7 were applied to differentiate between platelet-derived MVs (PMVs, CD41+ CD31+), endothelial cell-derived MVs (EMVs, CD41- CD31+) and Red blood cell-derived MVs (RMVs, CD235a+). Fluorescence minus one controls, a concentration row and detergent mediated degradation were used to confirm specific staining of MVs. Total MV numbers (Calcein + events) did not differ significantly between the three cardiac localizations. In the left atrial appendage, the proportion of PMV was significantly higher in permanent AF patients compared to non-permanent AF. EMV numbers only differed in the right atrium, where permanent AF patients exhibited significantly lower numbers of EMVs compared to no AF controls. No differences between the groups were detected for RMV.

Conclusion

In the present study, we found that PMV levels in the left atrial appendage correlate with the type of atrial fibrillation (permanent vs non-permanent). PMVs have been connected to platelet activation and thrombus formation. These results may help to better understand how different types of atrial fibrillation cause different rates of thrombus formation in the LAA.

PMV and EMV numbers by AF subtype

Funding Acknowledgement

Type of funding source: Public Institution(s). Main funding source(s): Medical Faculty University Bonn
Prevalence of atrial arrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy: a systematic review and meta-analysis
Authors: Rujirachun P , Wattanachayakul P , Charoenngam N , Winijkul A , Ungprasert P
Published: November 2020

Background and objectives

Little is known about atrial involvement in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). Recent studies have suggested that atrial arrhythmia (AA), including atrial fibrillation (AF), atrial flutter (AFL), and atrial tachycardia (AT), was common among these patients although the reported prevalence varied considerably across the studies.

Methods

We searched for published articles indexed in MEDLINE and EMBASE databases from inception through Sep 22, 2019 to identify cohort studies of patients with ARVC that described the prevalence of atrial arrhythmia among the participants. The pooled prevalence across studies was calculated.

Results

A total of 16 cohort studies with 1,986 patients with ARVC were included into this meta-analysis. The pooled prevalence of overall AA among patients with ARVC was 17.9% (95% CI, 13.0%–24.0%; I2 88%), the pooled prevalence of AF of 12.9% (95% CI, 9.6%–17.0%; I2 78%), the pooled prevalence of AFL of 5.9% (95% CI, 3.7%–9.2%; I2 70%), and the pooled prevalence of AT of 7.1% (95% CI, 3.7%–13.0%; I2 49%).

Conclusions

AA is common among patient with ARVC with the pooled prevalence of approximately 18%, which is substantially higher than the reported prevalence of AA in general population.

Funding Acknowledgement

Type of funding source: None
Left ventricular stiffness assessed by diastolic wall strain predicts asymptomatic atrial high rate episodes in patients with pacemaker implantation
Authors: Kishima H , Mine T , Fukuhara E , Ishihara M
Published: November 2020

Background

Asymptomatic atrial fibrillation has been reported to be associated with an increased risk of embolism.

Purpose

We investigated whether the left ventricular (LV) stiffness assessed by diastolic wall strain (DWS) predicts atrial high rate episodes (AHREs) in patients with pacemaker implantation (PMI).

Methods

One hundred forty seven patients (76 males, 75.2±8.9 years, 62 with sick sinus syndrome; SSS and 85 with atrioventricular block) who did not show atrial tachyarrhythmia before PMI were studied. DWS and other measurements were assessed using transthoracic echocardiography before DDD-pacemaker implantation. DWS was calculated from the M-mode echocardiographic measurement of the LV posterior wall thickness at end-systole (PWs) and end-diastole (PWd), and DWS was defined as (PWs-PWd)/PWs.

Results

AHREs (>5 min and >180 beats/min) were detected in 50/147 patients during follow-up periods (38.3±13.8 months). Patients with AHREs showed reduced DWS (0.29±0.07 vs. 0.39±0.06, p<0.0001), larger left atrial volume index, elevated E/e' ratio, thicker LV PWd, higher prevalence of SSS, and left bundle branch block pattern during ventricular pacing. On multivariate analysis, DWS was only independently associated with AHREs (p<0.0001, HR 1.987 for each 0.1 decrease in DWS, 95% CI 1.553–2.650). Patients with reduced DWS (<0.33) had a higher risk of incidences of AHREs (Figure 1).

Conclusions

LV stiffness assessed by DWS predicts AHREs in patients with PMI.

Figure 1

Funding Acknowledgement

Type of funding source: None
Amiodarone use in elderly atrial fibrillation patients with preserved ejection fraction is associated with increased short-term mortality
Authors: Li W , Tiwari N
Published: November 2020

Background

Amiodarone is commonly used in atrial fibrillation (AF). Long-term use of amiodarone is associated with significant toxicities, especially in elderly patients. However, in the short term after hospitalization of AF, it remains uncertain whether the use of amiodarone will increase mortality.

Methods

We conducted a retrospective cohort study including patients (Age≥60 years old) who were hospitalized between 07/01/2004 and 06/30/2019 with a primary diagnosis of AF and left ventricular ejection fraction (LVEF) ≥50%. Patients who were prescribed amiodarone during hospitalization but not before are considered as amiodarone group (348 patients). Patients who weren't prescribed amiodarone are considered as non-amiodarone group (2260 patients).

Univariate analysis solely analyzed amiodarone use on the all-cause mortality (Kaplan-Meier Curve), and possible confounders were adjusted in the multivariate analysis including age, gender, diabetes mellitus (DM), hypertension (HTN), coronary artery disease (CAD), as well as LVEF, left atrium internal diameter, use of other rate control medications (e.g. beta-blocker). The proportional-hazard assumption was tested by Log-rank test and a 2-sided P value of <0.05 is considered statistically significant. The hazard ratio and 95% confidence interval (CI) were calculated.

Results

Patients' baseline characteristics were listed in Table 1. Both Univariate and Multivariate analysis showed amiodarone group had higher in-hospital (hazard ratio 2.06; p=0.036) and 100-day mortality (hazard ratio 1.86; p=0.028). Other rate control medication use was also associated with increased mortality but not statistically significant. The results are showed in Figure 1.

Conclusion

Amiodarone use in elderly patients with preserved ejection fraction is associated with increased short-term all-cause mortality after hospitalization of AF.

Figure 1. KM Curve & ForestPlot of Mortality

Funding Acknowledgement

Type of funding source: None
Outcome of contact force-guided radiofrequency catheter ablation or second generation cryoballoon ablation for paroxysmal atrial fibrillation: propensity score matched analysis
Authors: Ukita K , Kawamura A , Nakamura H , Yasumoto K , Tsuda M , Okamoto N , Tanaka A , Matsunaga Y , Yano M , Egami Y , Shutta R , Nishino M , Tanouchi J
Published: November 2020

Background

Little has been reported on the outcome of contact force (CF)-guided radiofrequency catheter ablation (RFCA) and second generation cryoballoon ablation (CBA).

Purpose

The purpose of this study was to compare the outcome of CF-guided RFCA and second generation CBA for paroxysmal atrial fibrillation (PAF).

Methods

We enrolled the consecutive 364 patients with PAF who underwent initial ablation between September 2014 and July 2018 in our hospital. We compared the late recurrence of atrial tachyarrhythmia more than three months after ablation between RFCA group and CBA group. All RFCA procedures were performed using CF-sensing catheter and all CBA procedures were performed using second generation CB.

Results

There were significant differences in background characteristics: chronic kidney disease, serum brain natriuretic peptide level, and left ventricular ejection fraction. After propensity score matched analysis (Table), atrial tachyarrhythmia free survival was significantly higher in CBA group than in RFCA group (Figure).

Conclusions

Second generation CBA showed a significantly lower late recurrence rate compared to CF-guided RFCA.

Kaplan-Meier Curve

Funding Acknowledgement

Type of funding source: None
Risk factors and effective ablation strategy in patients presenting with left atrial flutter with no previous ablation for atrial fibrillation
Authors: Mohanty S , Trivedi C , Della Rocca D.G , Gianni C , Salwan A , Macdonald B , Mayedo A , Bassiouny M , Gallinghouse G.J , Burkhardt J.D , Horton R , Al-Ahmad A , Natale A
Published: November 2020

Background

A typical left atrial flutter (LAFL) may occur as a proarrhythmic complication of ablation for atrial fibrillation (AF).

Objective

We evaluated the risk factors and the best ablation strategy for LAFL in patients with no prior AF ablation.

Methods

Consecutive patients undergoing first catheter ablation for AFL with no prior procedure for AF were included in this prospective analysis. Based on the ablation strategy, patients were divided into, Group 1: PVI+ Flutter ablation (ablation of re-entry circuits) and Group 2: PVI+ Non-PV trigger ablation (targeting areas of focal activity as triggers). 3-D mapping of the LA was performed during tachycardia to identify the reentrant circuit.

PV isolation was performed in all patients. In group 1, ablation line was chosen to transect the area critical for the circuit (roof and mitral line). In group 2, ectopic beats arising from extra-PV foci detected by isoproterenol challenge were ablated. Off-drug success rate was assessed in all.

Results

A total of 92 and 90 patients were included in group 1 and 2 respectively. Baseline characteristics are provided in table 1. Pre-existent LA scar was detected in 91.3% and 90% of patients in group 1 and 2 respectively.

At 2 years of follow-up, 11/92 (12%) from group 1 and 60/90 (66.7%) from group 2 remained arrhythmia-free off-drugs (p<0.001). In the multivariate analysis, PVI +flutter ablation was detected to be associated with significantly high risk of recurrence [HR: 3.92 (95% CI: 2.52–6.1, p<0.001)]

Conclusion

In this series of patients presenting with LAFL with no earlier AF ablations, pre-existent left atrial scar was detected in majority of cases and PVI+ non-PV trigger ablation provided significantly better success rate than PVI+ flutter ablation.

Funding Acknowledgement

Type of funding source: None
Recurrent syncope, which patient should we follow more closely
Authors: Menezes Fernandes R , Mota T.F , Bispo J.S , Costa H , Azevedo P , Bento D , Marques N , Jesus I
Published: November 2020

Introduction

The importance of education is well recognized in patients presenting with syncope, in order to reduce the recurrence rate.

Purpose

To determine a predictive score of recurrent syncopal episodes after the first medical assessment.

Methods

We conducted a retrospective study enrolling patients followed in our Syncope Consultation from January 2015 to November 2019. Clinical and episodes characteristics, as well as diagnostic studies were analysed. Correlation between variables was performed by the Chi-square and T-Student tests, with a significance level of 95%. Independent predictors of recurrent syncope were identified through a binary logistic regression analysis, considering p=0.05. Then, a discriminatory function was applied using the Wilks lambda test to determine the discriminant score of the analysed groups. SPSS 24.0 was used for statistical analysis.

Results

A total of 694 patients were included, and 420 (60.5%) had recurrent syncope at the first evaluation. After educational approach, 97 (14%) maintained recurrent episodes. In this subgroup, the mean age was 63.7±22.8 years-old and 88.7% already had previous recurrent syncope (vs 56.1%; p<0.001). The prodrome of malaise was common (40.2% vs 26.8%; p=0.008), but 32% of these patients had syncope without prodromes (vs 21.8%; p=0.032). They also had frequently first-degree atrioventricular (AV) block (22.5% vs 6.8%; p<0.001) and 51.7% had a final diagnosis of reflex syncope. No previous medication with calcium channel blockers (CCB) (p<0.001), malaise (p=0.011), not having Q-waves in the electrocardiogram (p=0.022) and the presence of first-degree AV block (p<0.001) were independent predictors of recurrent syncope. A predictive score of recurrence was determined using the formula: 0.108 − 1.556 x (medication with CCB) + 0.989 x (malaise) − 1.031 x (Q-waves) + 2.406 x (first degree AV block). Variables should be replaced by 1 or 0, depending on whether the condition is present or not. A cut-off of 0.283 was obtained with a specificity of 96.1% and a discriminative power of 81.2%.

Conclusion

In our patients presenting with syncope, recurrence rate reduced from 60,5% to 14% just with educational measures. To help identify patients who maintain recurrence, we determined a predictive score using clinical data from the first visit, with a good discriminative power and excellent specificity. It could be used to strengthen education, to direct diagnostic studies and to shorten follow-up visits, but it still needs validation to be used in clinical practice.

Funding Acknowledgement

Type of funding source: None
Onset, severity and recovery of immediate orthostatic hypotension in normals and symptomatic patients: active standing and head-up tilt differ
Authors: Kohno R , Krishnappa D , Abe H , Benditt D.G
Published: November 2020

Background

Orthostatic hypotension (OH) occurring almost immediately (i.e., immediate OH, iOH) after movement to standing position is common, and may cause collapse due to instability or syncope. However, while “classic” OH (cOH) which typically occurs later is well-studied, iOH has received less attention.

Objectives

This study was designed to better understand blood pressure (BP) alterations associated with iOH in normal subjects and in symptomatic patients (pts) and to compare findings with both Active standing and Head-up tilt (HUT).

Methods

We studied 118 patients comprising 4 groups: 1) Normals (n=38), 2) Vasovagal syncope (VVS: n=27), 3) cOH (n=37), and 4) Primary Autonomic Failure (PAF, n=16). We compared timing and magnitude of BP fall and recovery during both drug-free “active standing” (≤10 min) and HUT (70°, ≤20 min). Continuous ECG and beat-to-beat BP were recorded. Statistical significance was tested using paired-t test and ANOVA as appropriate (significance: p≤0.05).

Results

Sex and BMI were similar among groups, but PAF pts tended to be older (62±17 yrs) vs Normals (44±16 yrs), VVS (32±12) and OH (45±21 yrs) pts. Time from upright posture to BP nadir was shorter with active standing vs HUT [p<0.005] except in PAF pts [p=NS]. Similarly, magnitude of BP fall (mmHg) tended to be greater with active standing in all groups (Normals −33±21 vs −20±18; VVS −28±16 vs −20±14; OH −37±16 vs −30±23; PAF −38±16 vs −34±28). Finally, except for PAF pts, BP recovery to baseline was shorter with active standing vs HUT (Table).

Conclusion

Active standing and HUT differ in evaluation of symptomatic pts. “Active standing” is associated with lesser time to BP nadir, greater BP fall, and faster BP recovery than with HUT. Additionally, iOH BP nadir typically occurs ≤15–20s after upright posture with rapid recovery necessitating beat-to-beat recordings to assess accurately.

Funding Acknowledgement

Type of funding source: None
Recurrent syncope in patients with a pacemaker and bradyarrhythmia
Authors: Lee C.J.Y , Davidsen J.M , Skals R , Torp-Pedersen C , Soegaard P
Published: November 2020

Objectives

To investigate the risk of recurrent syncope and all-cause mortality after implantation of a pacemaker in patients with bradyarrhythmia.

Background

A pacemaker is generally recommended when syncope is caused by bradyarrhythmias to prevent a new syncope. However, the occurrence and risk of recurrent syncope in patients with bradyarrhythmia after pacemakerimplantation are still unknown.

Methods

Patients with a prior syncope and an implantation of pacemaker were identified. Cumulative incidences of 5-years were estimated for the outcomes stratified into groups according to the type of bradyarrhythmia; and type of pacemaker. The risk of recurrent syncope and all-cause mortality were estimated using adjusted cox proportional hazard regressions.

Results

We identified 8,663 patients with a prior syncope and pacemaker implantation (median age of 78,1 years (SD 69,1–84,8) and 55,1% males). The 5-year cumulative incidence of recurrent syncope was 19,3% (95% confidence intervals (CI) 18,4–20,2). Factors associated with a significant increased risk of recurrent syncope were male sex, age 80 years and above, alcohol related disease, bleeding, chronic obstructive pulmonary disease, chronic kidney disease, stroke, and malignancy. Atrial fibrillation was associated with a significantly decreased risk of recurrent syncope. Patients with an advanced AV conduction abnormality had a lower associated risk of syncope compared to patients with sinus node dysfunction (HR 0,85, 95% CI 0,76–0,94, p=0,003).

Conclusions

One fifth of the cohort had a recurrence syncope after five years. Besides older age and male sex, several comorbidities were found to be associated with a higher risk of recurrence of syncope. Clinicians need to be attentive that a large proportion of patients with bradyarrhythmia suffer from syncope even when treated with a pacemaker.

Funding Acknowledgement

Type of funding source: None
ICD-detected respiratory disturbance index: accuracy for sleep apnea detection and prognostic value
Authors: Boriani G , D'Onofrio A , Pisano E , Pieragnoli P , Locatelli A , Capucci A , Talarico A , Sinagra G , Rapacciuolo A , Piacenti M , Indolfi C , Checchinato C , Ricci R.P
Published: November 2020

Purpose

In patients affected by heart failure an association exists between sleep apnea (SA) measured by polysomnography and adverse outcome. Impedance-based implantable cardioverter defibrillator (ICD) algorithms have been designed to compute the Respiratory Disturbance Index (RDI) to identify severe SA. The purpose of the DASAP-HF study was to evaluate the accuracy of RDI for the prediction of severe SA, and investigate the prognostic value of device-detected RDI values.

Methods

Patients with left ventricular ejection fraction ≤35% implanted with an ICD were enrolled and followed for 24 months. One month after implantation, patients underwent a polysomnographic study (PS) for assessing the apnea-hypopnea index (AHI). The average RDI value was calculated over a 1-week period preceding the sleep study and compared with the assessment of severe SA at PS (AHI ≥30 episodes/h). The endpoint was all-cause death after 24 months.

Results

224 out of 265 enrolled patients had usable RDI values. Patients characteristics: 79% male, 67±10 years, BMI 27±7kg/m2, ejection fraction 29±5%, 54% ischemic cardiomyopathy, 50% CRT-D. The mean AHI value at PS was 21±15 episodes/h. The mean RDI value recorded during the week preceding PS was 30±16 episodes/h. RDI values accurately identified severe SA diagnosed at PS (AUC 0.77; 95% CI 0.70–0.83; P=0.001). Based on the ROC curve analysis, RDI ≥29 episodes/h and AHI ≥17 episodes/h maximized sensitivity and specificity for the prediction of death. Both indexes were independently associated with all-cause death but, after correction for the other independent significant prognostic variables, RDI≥29episodes/h yielded stronger prediction (HR: 12.22, 95% CI:1.64–91.37, p=0.015) as compared to AHI ≥17episodes/h (HR: 4.14, 95% CI:1.17–14.66, p=0.028). Moreover, severe SA diagnosed at PS (AHI ≥30episodes/h) was not associated with death (HR: 1.20, 95% CI:0.3817–3.8266, p=0.761).

Conclusions

In heart failure patients indicated to ICD, severe SA was confirmed to be associated with survival. The ICD-measured RDI accurately identified severe SA detected at PS, and was associated with the risk of death at long-term.

Funding Acknowledgement

Type of funding source: Private company. Main funding source(s): Boston Scientific
Increased 5-year risk of stroke, atrial fibrillation, acute coronary syndrome and heart failure in out-of-hospital cardiac arrest survivors relative to population controls: a nationwide register-based
Authors: Kragholm K , Bundgaard K , Wissenberg M , Folke F , Lippert F , Gislason G , Kober L , Sogaard P , Lip G.Y.H , Torp-Pedersen C
Published: November 2020

Background

Out-of-hospital cardiac arrest (OHCA) survivors are a selected group of patients with younger age and less comorbid conditions relative to non-survivors. Long-term risk of stroke, atrial fibrillation or flutter (AF), acute coronary syndrome (ACS) and heart failure (HF) in OHCA survivors not diagnosed with any of these conditions as part of the cardiac arrest is unknown.

Purpose

To examine 5-year risk of stroke, AF, ACS and HF in 30-day OHCA survivors relative to age- and sex-matched population controls.

Methods

OHCA 30-day survivors and age- and sex-matched population controls not previously diagnosed with stroke, AF, ACS or HF or during the first 30 days after cardiac arrest were included using Danish Cardiac Arrest Registry data from 2001–2015 as well as the Danish Civil Registration System. Characteristics are compared using totals and percentages for categorical data and median and 25–75% percentiles for continuous data. Five-year outcomes are compared using cumulative incidence plots as well as Shared Frailty Cox regression modeling, unadjusted and adjusted for potential confounders including age, sex, hypertension, diabetes, chronic obstructive pulmonary disease (COPD), peripheral arterial disease (PAD), chronic ischemic heart disease (IHD), transient ischemic attack (TIA), thyroid disease, cholesterol-lowering, antiplatelet and anticoagulant agents.

Results

Of 4362 30-day survivors, 1063 were stroke-, AF-, ACS- and HF-naïve and 1051 were matched to population controls using age, sex and time of OHCA event as matching variables. The figure depicts the risk of stroke beyond day 30 to 5 years of follow-up was 4.7% versus 1.7% for OHCA survivors vs. controls. Risks of AF, ACS and HF were 7.0% vs. 2.1%, 4.7% versus 1.2% and 12.2% vs. 1.0%, respectively. OHCA 30-day survivors were significantly more likely to have PAD relative to controls, 4.9% vs. 1.1%. Differences in IHD (22.0% vs. 1.7%), hypertension (28.1% vs. 14.6%), diabetes (9.5% vs. 4.1%), lipid-lowering agents (27.6% vs. 9.5%), COPD (11.3% vs. 2.2%) were also significant. When adjusting for these comorbidities as well as for thyroid diseases, chronic kidney disease, cancer, antiplatelet and anticoagulant therapy, differences remained highly significant: HR stroke 3.33 [95% CI 2.21–5.02], HR AF 3.26 [2.28–4.66], HR ACS 3.36 [2.14–5.27] and HR HF 11.50 [8.02–16.48].

Conclusion

We demonstrate an increased five-year risk of stroke, atrial fibrillation or flutter, acute coronary syndrome and heart failure in out-of-hospital cardiac arrest survivors without prior existence of any of these conditions. These results indicate that OHCA survivors continue to remain high-risk patients for cardiovascular events and prevention intervention is warranted.

Funding Acknowledgement

Type of funding source: None
Efficacy of epicardial and endocardial ablation in the prevention of ventricular tachycardia in arrythmogenic right ventricular cardiomyopathy- a meta analysis
Authors: Sattar Y , Ullah W , Mamtani S , Alraies C
Published: November 2020

Introduction

Ventricular tachycardia is a major complication associated with increased risk of sudden cardiac death in arrhythmogenic ventricular cardiomyopathy. Recurrence of VT status post catheter endocardial ablation with conventional mapping is a evolving discussion in management of VT prevention in ARVC. With the evolution of new mapping techniques to locate ectopic foci of VT, a combination of endo- and epicardial catheter ablation have proven to be efficacious in the prevention of frequency of VT recurrence and its duration.

Methods

Using PubMed, Ovid (MEDLINE) and Cochrane database we searched using the MeSH terms including: “arrhythmogenic right ventricular cardiomyopathy”, “arrhythmogenic right ventricular dysplasia”, “monomorphic ventricular tachycardia”, “polymorphic ventricular Tachycardia”, “endocardial catheter ablation”, “epicardial catheter ablation”. The primary outcomes were to assess VT frequency and duration status post endocardial or epicardial or a combination of both types of ablation. The secondary outcome includes sudden cardiac arrest or sudden cardiac death after procedure. ANOVA with post HOC analysis was performed using SPSS v.26 (IBM Corp, NY, USA)

Results

A total of 33 studies included 1437 patients with a mean male=67%. The data analysis showed a mean VT prevention for endocardial ablation was 65%, epicardial 78%, and for combined epi-endocardial was 89% (figure-1). The mean procedural mortality rate was 2%. In order to test the hypothesis that combined epi-endocardial ablation was more successful in the prevention of VT recurrence, we performed a one-way analysis of variance (ANOVA). The analysis was statistically significant F(2,14)=5.879, 95% CI, p=0.014. Post Hoc test (Tukey HSD test) with multiple comparisons indicated that patients who underwent combined epi-endocardial ablation experienced a statistically significant difference in VT prevention of 89% (95% CI p=0.01) compared to only endocardial ablation, mean VT prevention of 65% (95% CI, p=0.189) or only epicardial, mean VT prevention of 78% (95% CI, p=0.353).

Conclusion

With new mapping techniques, use of endocardial, and epicardial ablation is linked to decrease VT frequency, duration, ICD shocks, and sudden cardiac death in patients with ARVC in cohorts with prior failure of antiarrhythmics.

Total VT Prevention across target sites

Funding Acknowledgement

Type of funding source: None
Activation pattern during his pacing: how close are we to normal physiology?
Authors: Yasin O , Vaidya V , Tri J , Van Zyl M , Ladejobi A , Xiao P , Han J , Scheuermann C , Bush J , Taubel R , Pedersen J , Yngsdal L , Asirvatham S , Cha Y
Published: November 2020

Background

His bundle pacing aims to mimic the activation pattern of normal conduction to maintain ventricular synchrony. However, selective His capture can be challenging, and the activation sequence during His pacing may not replicate normal conduction.

Purpose

Compare the right ventricular (RV) and left ventricular (LV) activation pattern in sinus rhythm and His bundle pacing.

Methods

Baseline LV and RV map was created in sinus rhythm using Rhythmia mapping system (Boston Scientific Corporation) in canine animal model. Medtronic 3830 lead was placed near the bundle of His under fluoroscopic, intracardiac echocardiogram, and electroanatomic guidance. Conduction system capture was confirmed by observing a QRS duration <120ms and an isoelectric segment between pacing artifact and QRS on surface ECG. Repeat LV and RV activation map was obtained during His pacing. Average QRS, HV and pacing to V intervals were calculated with standard deviation.

Results

Mapping was performed successfully in four animals. At baseline, the average QRS duration was 44±2.6ms and HV interval was 32±4.2ms. Earliest site of myocardial activation was in the mid-septal LV region. The earliest RV myocardial activation was also at the septum closer to the apex, but later than the LV (Figure1A). With His pacing, the average QRS duration was 70±17.0ms and the average stim to V interval was 31±8.7ms. During His pacing, the earliest site of activation was in the RV septum, with an activation pattern from base to apex in both the RV and LV.

Conclusion

Unlike normal physiology, the activation pattern during conduction system pacing is from base to apex with earliest site in the RV.

Funding Acknowledgement

Type of funding source: Public hospital(s). Main funding source(s): Mayo Clinic